Obinutuzumab

In a video interview, Matthew Cortese, MD, MPH, discusses how to approach initial treatment of CLL.

A simultaneous, multidrug, multi-targeted treatment regimen produced remissions in patients with certain types of relapsed or refractory diffuse large B-cell lymphoma in a phase 1b/phase 2 study.

Healio spoke with Ryan. W. Jacobs, MD, about survivorship in CLL.

Healio spoke with Ryan. W. Jacobs, MD, about treatment options available to patients with CLL.

SAN DIEGO — Obinutuzumab use increases the chances of achieving complete renal response and lowers the risk for kidney-related events and time to flare in lupus nephritis, according to data presented at ACR Convergence 2023.

This year’s ASCO Annual Meeting included essential research updates across the field.

In this video, Jakub Svoboda, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.

In this video, Jakub Svoboda, MD, discusses updated data on the results of the MOLTO study into Richter syndrome presented at ASCO Annual Meeting.

CHICAGO – In this Healio video exclusive, Christopher Flowers, MD, discusses how the combination of zanubrutinib and obinutuzumab vs. obinutuzumab alone leads to longer PFS in patients with relapsed/refractory follicular lymphoma.

In this video, Michael Choi, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.